Vir Biotechnology Inc (VIR)
Number of days of payables
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Payables turnover | 0.44 | 2.20 | 2.44 | 4.78 | 22.78 | 72.45 | 17.21 | 14.24 | 10.10 | 2.13 | 0.10 | 0.00 | 0.00 | -3.93 | -3.99 | ||||
| Number of days of payables | days | 836.13 | 166.25 | 149.52 | 76.35 | 16.02 | 5.04 | 21.20 | 25.63 | 36.14 | 171.73 | 3,519.83 | — | — | — | — |
December 31, 2023 calculation
Number of days of payables = 365 ÷ Payables turnover
= 365 ÷ 0.44
= 836.13
The number of days of payables for Vir Biotechnology Inc has exhibited significant fluctuations over the past eight quarters. In Q4 2023, the company's payables were outstanding for an extended period of 836.13 days, a substantial increase compared to the previous quarter's figure of 166.25 days. This indicates that the company took a longer time to settle its payables in Q4 2023, potentially impacting its cash flow and liquidity position.
Historically, there has been a trend of increasing number of days of payables from Q1 2022 to Q4 2023, with occasional fluctuations. The sharp increase in payables outstanding in Q4 2023 may raise concerns about the company's ability to manage its working capital efficiently and meet its financial obligations in a timely manner.
It is important for investors and analysts to closely monitor Vir Biotechnology Inc's payables management practices and assess the reasons behind the significant increase in the number of days of payables in order to evaluate the company's overall financial health and sustainability.
Peer comparison
Dec 31, 2023